Comparison of population characteristics, treatment modes, and clinical outcomes of patients with advanced non-small cell lung cancer in clinical trials and in the real world received PD-1/PD-L1 inhibitor.

Zhiyong Ma,Huijuan Wang,Chunhua Wei,Zhang Guo-wei,Xiangtao Yan,Mina Zhang,Xiaojuan Zhang,Yuanyuan Niu,Jinpo Yang

Comparison of population characteristics, treatment modes, and clinical outcomes of patients with advanced non-small cell lung cancer in clinical trials and in the real world received PD-1/PD-L1 inhibitor.

2021

Zhiyong Ma
Huijuan Wang
Chunhua Wei
Zhang Guo-wei
Xiangtao Yan
Mina Zhang
Xiaojuan Zhang
Yuanyuan Niu
Jinpo Yang

e18733Background: Although PD-1/PD-L1 inhibitors have become the standard treatment for patients with advanced non-small cell lung cancer (NSCLC), data from clinical trials are difficult to be veri...

Keywords:

Population
Lung cancer
PD-L1 inhibitor
Medicine
Internal medicine
non small cell
Oncology
Standard treatment
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations